Claims
- 1. A compound of formula 1
- 2. The compound of formula 1 according to claim 1, wherein:
X− is an anion with a single negative charge selected from chloride, bromide, methylsulfate, 4-toluenesulfonate, and methanesulfonate; R1 and R2, which are identical or different, are each a group selected from methyl, ethyl, n-propyl, and isopropyl, which are optionally substituted by hydroxy or fluorine; R3, R4, R5, and R6, which are identical or different, are each hydrogen, methyl, ethyl, methyloxy, ethyloxy, hydroxy, fluorine, chlorine, bromine, CN, CF3, or NO2; and R7 is methyl, ethyl, methyloxy, ethyloxy, —CH2—F, —CH2—CH2—F, —O—CH2—F, —O—CH2—CH2—F, —CH2—OH, —CH2—CH2—OH, CF3, —CH2—OMe, —CH2—CH2—OMe, —CH2—OEt, —CH2—CH2OEt, —O—COMe, —O—COEt, —O—COCF3, —O—COCF3, fluorine, chlorine, or bromine.
- 3. The compound of formula 1, according to claim 2, wherein:
X− is an anion with a single negative charge selected from chloride, bromide, and methanesulfonate; R1 and R2, which are identical or different, are each methyl or ethyl, which are optionally substituted by hydroxy or fluorine; R3, R4, R5, and R6, which are identical or different, are each hydrogen, methyl, ethyl, methyloxy, ethyloxy, hydroxy, fluorine, chlorine, or bromine; and R7 is methyl, ethyl, methyloxy, ethyloxy, CF3, or fluorine.
- 4. The compound of formula 1, according to claim 3, wherein:
X− is bromide; R1 and R2, which are identical or different, are each methyl or ethyl; R3, R4, R5, and R6, which are identical or different, are each hydrogen, methyl, methyloxy, chlorine, or fluorine; and R7 is methyl or fluorine.
- 5. The compound of formula 1, according to claim 4, wherein:
X− is bromide; R1 and R2, which are identical or different, are each methyl or ethyl; R3, R4, R5, and R6, which are identical or different, denote hydrogen or fluorine; and R7 is methyl or fluorine.
- 6. A method of treating a disease that is responsive to anticholinergic activity, comprising administering to a host in need thereof an effective amount of a compound of formula 1 according to one of claims 1 to 5.
- 7. A method according to claim 6, wherein the disease is selected from asthma, COPD, vagally induced sinus bradycardia, heart rhythm disorders, spasms in the gastrointestinal tract, spasms in the urinary tract, and menstrual disorders.
- 8. A pharmaceutical composition comprising one or more compounds of formula 1 according to one of claims 1 to 5, or a physiologically acceptable salt thereof, optionally together with one or more conventional excipients and/or carriers.
- 9. A pharmaceutical composition according to claim 8, further comprising at least one additional active substance selected from the group consisting of: betamimetics, antiallergic agents, PAF-antagonists, leukotriene-antagonists, and steroids.
- 10. A process for preparing a compound of formula 1 according to claim 1
- 11. A compound of formula 4
Priority Claims (1)
Number |
Date |
Country |
Kind |
DE 100 50 994.0 |
Oct 2000 |
DE |
|
RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser. No. 09/976,950, for which priority is claimed. Furthermore, benefit of U.S. Provisional Application Serial No. 60/252,777, filed on Nov. 22, 2000 is hereby claimed. Moreover, each of these applications is incorporated by reference herein.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60252777 |
Nov 2000 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09976950 |
Oct 2001 |
US |
Child |
10684994 |
Oct 2003 |
US |